Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):952–958. doi: 10.1038/sj.bjc.6690152

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer

M M Borner 1, P Brousset 2, B Pfanner-Meyer 1, M Bacchi 3, S Vonlanthen 1, M A Hotz 1, H J Altermatt 1, D Schlaifer 2, J C Reed 4, D C Betticher 1
PMCID: PMC2362678  PMID: 10070896

Abstract

Proteins of the Bcl-2 family as well as p53 are important regulators of apoptosis. Alterations in the expression of these proteins can contribute to the formation of cancer, as well as influence tumour response to chemo- and radiotherapy. We used antibodies specific for the human Bcl-2, Mcl-1, Bax, Bak and p53 proteins to examine the expression of these apoptosis-regulating genes in 49 archival specimens of patients with radically resected non-small-cell lung cancer (NSCLC). Tumour cells containing immunostaining for the antiapoptotic proteins Bcl-2 and Mcl-1 were present in 31% and 58% of the cases evaluated, respectively, whereas immunopositivity for the proapoptotic proteins Bax and Bak was found in 47% and 58% of the samples. p53 immunopositivity was detected in 61% of the samples. The expression of Bcl-2 and p53 and the expression of Mcl-1 and Bax showed a positive association (P= 0.02 and P= 0.06 respectively), whereas the expression of Bax was inversely related to p53 (P= 0.008). The expression of Bcl-2 had a negative influence on relapse-free survival in this population of primary resected NSCLC patients (P= 0.02). The expression of p53 and Bcl-2 was significantly associated with metastasis-free survival (P< 0.01). Only patients with p53-positive tumours developed metastases during the follow-up period. Our results establish the frequent expression of the Bcl-2 family proteins Bcl-2, Mcl-1, Bax and Bak in NSCLC. It can be expected that Bcl-2 family members have no straightforward impact on clinical outcome in this disease because their interactions in the regulation of apoptosis are complex. © 1999 Cancer Research Campaign

Keywords: non-small-cell lung cancer, p53, Bcl-2, Mcl-1, Bax, Bak

Full Text

The Full Text of this article is available as a PDF (377.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apolinario R. M., van der Valk P., de Jong J. S., Deville W., van Ark-Otte J., Dingemans A. M., van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997 Jun;15(6):2456–2466. doi: 10.1200/JCO.1997.15.6.2456. [DOI] [PubMed] [Google Scholar]
  2. Betticher D. C., Heighway J., Hasleton P. S., Altermatt H. J., Ryder W. D., Cerny T., Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996 Feb;73(3):294–300. doi: 10.1038/bjc.1996.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994 Jan-Feb;44(1):7–26. doi: 10.3322/canjclin.44.1.7. [DOI] [PubMed] [Google Scholar]
  4. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem. 1996 May 31;271(22):12695–12698. doi: 10.1074/jbc.271.22.12695. [DOI] [PubMed] [Google Scholar]
  5. Borner M. M., Joncourt F., Hotz M. A. Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer. 1997;76(11):1448–1454. doi: 10.1038/bjc.1997.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Borner M. M., Myers C. E., Sartor O., Sei Y., Toko T., Trepel J. B., Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 1995 May 15;55(10):2122–2128. [PubMed] [Google Scholar]
  7. Brambilla E., Gazzeri S., Moro D., Caron de Fromentel C., Gouyer V., Jacrot M., Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 1993 Jul;143(1):199–210. [PMC free article] [PubMed] [Google Scholar]
  8. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., Coll J. L. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol. 1996 Dec;149(6):1941–1952. [PMC free article] [PubMed] [Google Scholar]
  9. Brousset P., Benharroch D., Krajewski S., Laurent G., Meggetto F., Rigal-Huguet F., Gopas J., Prinsloo I., Pris J., Delsol G. Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood. 1996 Mar 15;87(6):2470–2475. [PubMed] [Google Scholar]
  10. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  11. Eerola A. K., Törmänen U., Rainio P., Sormunen R., Bloigu R., Vähäkangas K., Lehto V. P., Soini Y., Päkkö P. Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. J Pathol. 1997 Feb;181(2):172–177. doi: 10.1002/(SICI)1096-9896(199702)181:2<172::AID-PATH715>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  12. Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994 Aug 26;78(4):539–542. doi: 10.1016/0092-8674(94)90518-5. [DOI] [PubMed] [Google Scholar]
  13. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C. A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995 May;71(5):1003–1007. doi: 10.1038/bjc.1995.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fujino M., Dosaka-Akita H., Harada M., Hiroumi H., Kinoshita I., Akie K., Kawakami Y. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer. 1995 Dec 15;76(12):2457–2463. doi: 10.1002/1097-0142(19951215)76:12<2457::aid-cncr2820761209>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. Harpole D. H., Jr, Herndon J. E., 2nd, Wolfe W. G., Iglehart J. D., Marks J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995 Jan 1;55(1):51–56. [PubMed] [Google Scholar]
  16. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  17. Harris C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996 Oct 16;88(20):1442–1455. doi: 10.1093/jnci/88.20.1442. [DOI] [PubMed] [Google Scholar]
  18. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  19. Jacobson M. D., Weil M., Raff M. C. Programmed cell death in animal development. Cell. 1997 Feb 7;88(3):347–354. doi: 10.1016/s0092-8674(00)81873-5. [DOI] [PubMed] [Google Scholar]
  20. Kinzler K. W., Vogelstein B. Life (and death) in a malignant tumour. Nature. 1996 Jan 4;379(6560):19–20. doi: 10.1038/379019a0. [DOI] [PubMed] [Google Scholar]
  21. Krajewska M., Fenoglio-Preiser C. M., Krajewski S., Song K., Macdonald J. S., Stemmerman G., Reed J. C. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol. 1996 Nov;149(5):1449–1457. [PMC free article] [PubMed] [Google Scholar]
  22. Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996 May;148(5):1567–1576. [PMC free article] [PubMed] [Google Scholar]
  23. Krajewski S., Bodrug S., Krajewska M., Shabaik A., Gascoyne R., Berean K., Reed J. C. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995 Jun;146(6):1309–1319. [PMC free article] [PubMed] [Google Scholar]
  24. Krajewski S., Krajewska M., Reed J. C. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res. 1996 Jun 15;56(12):2849–2855. [PubMed] [Google Scholar]
  25. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H. G., Reed J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994 Dec;145(6):1323–1336. [PMC free article] [PubMed] [Google Scholar]
  26. Lee J. S., Yoon A., Kalapurakal S. K., Ro J. Y., Lee J. J., Tu N., Hittelman W. N., Hong W. K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995 Aug;13(8):1893–1903. doi: 10.1200/JCO.1995.13.8.1893. [DOI] [PubMed] [Google Scholar]
  27. Liloglou T., Ross H., Prime W., Donnelly R. J., Spandidos D. A., Gosney J. R., Field J. K. p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. Br J Cancer. 1997;75(8):1119–1124. doi: 10.1038/bjc.1997.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Miyashita T., Harigai M., Hanada M., Reed J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994 Jun 15;54(12):3131–3135. [PubMed] [Google Scholar]
  29. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., Buyse M., Menard S., Pierotti M., Rilke F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997 Aug;15(8):2858–2865. doi: 10.1200/JCO.1997.15.8.2858. [DOI] [PubMed] [Google Scholar]
  30. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993 Sep 2;329(10):690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  31. Potten C. S. What is an apoptotic index measuring? A commentary. Br J Cancer. 1996 Dec;74(11):1743–1748. doi: 10.1038/bjc.1996.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Quinlan D. C., Davidson A. G., Summers C. L., Warden H. E., Doshi H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992 Sep 1;52(17):4828–4831. [PubMed] [Google Scholar]
  33. Reed J. C. Double identity for proteins of the Bcl-2 family. Nature. 1997 Jun 19;387(6635):773–776. doi: 10.1038/42867. [DOI] [PubMed] [Google Scholar]
  34. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  35. Törmänen U., Eerola A. K., Rainio P., Vähäkangas K., Soini Y., Sormunen R., Bloigu R., Lehto V. P., Päkkö P. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 1995 Dec 1;55(23):5595–5602. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES